Dose-escalated therapy involving a single agent produced complete and partial responses in patients with different B-cell malignancies.
-----
Related Content
Maintenance Therapy Effective in Treating Diffuse Large B-Cell Lymphoma
Maintenance Therapy After Autologous Stem Cell Transplant Improves Survival in MCL
-----
Rituximab, a chimeric monoclonal antibody targeting CD20 antigen on B-cells, is considered a standard of care in the treatment of B-cell malignancies (standard dose: 375 mg/m2), especially in combination with cytotoxic chemotherapy as induction therapy or as a single agent for induction and maintenance therapy. Positive activity has been reported in multiple types of B-cell lymphoma, such as diffuse large cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, lymphocyte predominant Hodgkin lymphoma, and Waldenström macroglobulinemia. Dose-escalation of rituximab as a single agent has shown improved activity in previously treated, poor prognosis chronic lymphocytic leukemia.
Lauren M Jacobs, BS, George Washington University, and colleagues presented 4 cases of patients with B-cell malignancies (chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, and Waldenström macroglobulinemia) who received dose-escalated rituximab as a single agent after declined cytotoxic chemotherapy. All patients received weekly induction doses for 4 weeks, starting at 375-500 mg/m2 and then followed by weekly or monthly dose escalation to 1500 mg/m2. Researchers presented their findings at the American Federation for Clinical Research (Washington DC; April 18, 2017).
Results of the dose-escalation rituximab treatment showed 3 patients (chronic lymphocytic leukemia, mantle cell lymphoma, and follicular lymphoma) achieved complete responses and 1 patient (Waldenström macroglobulinemia) achieved stable disease/partial response. After treatment conclusion, all patients maintained their response for 6.5 to longer than 15 years.
Minimal toxicities were reported as a result of rituximab treatment. Only initial infusion reactions similar to those observed with standard dose infusions were reported. Additionally, there were no serious treatment-related adverse events or infections observed in the patient population.
Researchers concluded that dose-escalated rituximab as a single agent may possibly be curative for some patients with B-cell malignancies. Further studies are required to validate these findings. – Zachary Bessette
